Instituto San Marcos | San Juan, Argentina

Research site

(Unclaimed)

Location

Calle D. F. Sarmiento 92 norte, San Juan, San Juan, Argentina

Site insights

Top conditions

Top treatments

Pembrolizumab

Anastrozole

Letrozole

Imlunestrant

Tamoxifen

MK-3475-859

Exemestane

Abemaciclib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 6 total trials

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cance...

Enrolling

Breast Neoplasms

Drug: Anastrozole

Drug: Tamoxifen

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3)

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaci...

Active, not recruiting

Neoplasm Metastasis

Breast Neoplasms

Drug: Imlunestrant

Drug: Abemaciclib

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab (MK-3475A) administered subcutaneously (...

Enrolling

Melanoma

Renal Cell Carcinoma

Biological: Pembrolizumab

Biological: Pembrolizumab co-formulated with hyaluronidase

Locations recently updated

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus ch...

Enrolling

Metastatic Esophageal Squamous Cell Carcinoma

Drug: Oxaliplatin

Drug: Levoleucovorin

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in combination with chemotherapy (Cisplatin combined with 5-Fluorour...

Active, not recruiting

Stomach Neoplasms

Drug: capecitabine

Drug: Cisplatin

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's...

Active, not recruiting

Breast Neoplasms

Drug: dextrose

Drug: liposomal doxorubicin

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms